The Metabolic-Inflammatory Axis in Brain Aging and Neurodegeneration

Front Cover
Fei Yin, Jia Yao, Roberta Diaz Brinton, Enrique Cadenas
Frontiers Media SA, Aug 16, 2017

 Impairment of energy metabolism is a hallmark of brain aging and several neurodegenerative diseases, such as the Alzheimer’s disease (AD). Age- and disease-related hypometabolism is commonly associated with oxidative stress and they are both regarded as major contributors to the decline in synaptic plasticity and cognition. Neuroinflammatory changes, entailing microglial activation and elevated expression of inflammatory cytokines, also correlate with age-related cognitive decline. It is still under debate whether the mitochondrial dysfunction-induced metabolic deficits or the microglia activation-mediated neuroinflammation is the initiator of the cognitive changes in aging and AD. Nevertheless, multiple lines of evidence support the notion that mitochondrial dysfunction and chronic inflammation exacerbate each other, and these mechanistic diversities have cellular redox dysregulation as a common denominator. 


This research topic focuses on the role of a metabolic-inflammatory axis encompassing the bioenergetic activity, brain inflammatory responses and their redox regulation in healthy brain aging and neurodegenerative diseases. Dynamic interactions among these systems are reviewed in terms of their causative or in-tandem occurrence and how the systemic environment, –e.g., insulin resistance, diabetes, and systemic inflammation–, impacts on brain function. 

 

Contents

The MetabolicInflammatory Axis in Brain Aging and Neurodegeneration
5
Neurovascular and neurometabolic derailment in aging and Alzheimers disease
8
relevance for neurodegeneration and aging
16
Mitochondrial Haplotype APOE Genotype and Chromosomal Sex
21
Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction
35
Microglial cell dysregulation in brain aging and neurodegeneration
52
Oxidized cholesterol as the driving force behind the development of Alzheimers disease
73
Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimers disease
94
interactive risk factors for Alzheimers disease
102
Creactive protein advanced glycation end products and their receptor in type 2 diabetic elderly patients with mild cognitive impairment
116
Astrocytic estrogen receptors and impaired neurotrophic responses in a rat model of perimenopause
125
Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment
131
Hematopoietic cytokines as therapeutic players in early stages Parkinsons disease
142
Protective effects of ginseng on neurological disorders
147
Back Cover
160
Copyright

Common terms and phrases

Bibliographic information